COMPANY LETTERHEAD]Publicity and Board Observer Rights Agreement • April 9th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [__] and/or one or more of its Affiliates (as defined below) (each, an “Investor” and together, the “Investors”), the parties to this letter hereby agree as follows:
